Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review.
Details
Serval ID
serval:BIB_D62D546FA130
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review.
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases
ISSN
1124-0490 (Print)
ISSN-L
1124-0490
Publication state
Published
Issued date
10/2011
Peer-reviewed
Oui
Volume
28
Number
2
Pages
87-94
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
This study was designed to systematically review the emerging role of whole-body positron emission tomography (PET) with 18F-Fluorodeoxyglucose (FDG) in patients with sarcoidosis.
A comprehensive literature search of published studies through December 2010 in PubMed/MEDLINE and Embase databases regarding whole-body FDG-PET and PET/CT in patients with sarcoidosis was performed.
Ultimately, we identified nine studies comprising a total of 379 patients with sarcoidosis. Main findings of the included studies are presented.
from this systematic review we can summarize that: (1) positive FDG-PET findings should be interpreted with caution in differentiating sarcoidosis from other inflammatory diseases and malignant abnormalities; (2) FDG-PET seems to be a very useful molecular imaging method in assessing disease activity, in staging and identifying occult sites, and in monitoring treatment response in patients with sarcoidosis; (3) FDG-PET shows a better diagnostic accuracy compared to 67Ga scintigraphy in patients with sarcoidosis, because of a better sensitivity of FDG-PET (mainly due to the high quality of FDG-PET images with superior contrast and spatial resolution compared to 67Ga scintigraphy) in addition to several practical advantages (less radiation exposure, shorter time between injection and imaging).
A comprehensive literature search of published studies through December 2010 in PubMed/MEDLINE and Embase databases regarding whole-body FDG-PET and PET/CT in patients with sarcoidosis was performed.
Ultimately, we identified nine studies comprising a total of 379 patients with sarcoidosis. Main findings of the included studies are presented.
from this systematic review we can summarize that: (1) positive FDG-PET findings should be interpreted with caution in differentiating sarcoidosis from other inflammatory diseases and malignant abnormalities; (2) FDG-PET seems to be a very useful molecular imaging method in assessing disease activity, in staging and identifying occult sites, and in monitoring treatment response in patients with sarcoidosis; (3) FDG-PET shows a better diagnostic accuracy compared to 67Ga scintigraphy in patients with sarcoidosis, because of a better sensitivity of FDG-PET (mainly due to the high quality of FDG-PET images with superior contrast and spatial resolution compared to 67Ga scintigraphy) in addition to several practical advantages (less radiation exposure, shorter time between injection and imaging).
Keywords
Adult, Diagnosis, Differential, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Positron-Emission Tomography, Predictive Value of Tests, Prognosis, Radiopharmaceuticals, Sarcoidosis/diagnostic imaging, Sarcoidosis/therapy, Severity of Illness Index, Whole Body Imaging
Pubmed
Web of science
Create date
20/08/2017 22:11
Last modification date
20/08/2019 16:56
Usage data
